Galderma Group AG Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Net Income	863	613	231	-57
Depreciation & Amortization	329	323	293	276
Stock-Based Compensation	62	64	68	-
Other Adjustments	107	115	134	68
Change in Receivables	-218	-89	-208	47
Changes in Inventories	-156	-88	-12	31
Changes in Accounts Payable	276	266	64	-66
Changes in Accrued Expenses	126	124	72	-13
Changes in Income Taxes Payable	-163	-124	-90	-87
Changes in Other Operating Activities	-17	-19	-64	-34
Operating Cash Flow	1,206	1,185	488	165
Operating Cash Flow Growth	1.77%	142.83%	195.76%	-
Capital Expenditures	-126	-113	-128	-121
Purchases of Intangible Assets	-19	-41	-147	-32
Cash Acquisitions	-	-	-50	-25
Other Investing Activities	-	-	-	4
Investing Cash Flow	-145	-154	-326	-174
Long-Term Debt Issued	850	1,408	3,601	856
Long-Term Debt Repaid	-1,065	-1,701	-5,777	-1,725
Net Long-Term Debt Issued (Repaid)	-215	-293	-2,176	-869
Issuance of Common Stock	-	-	2,166	1,011
Repurchase of Common Stock	-342	-363	-15	-
Net Common Stock Issued (Repurchased)	-342	-363	2,151	1,011
Common Dividends Paid	-104	-41	-	-
Other Financing Activities	-25	-30	-32	-
Financing Cash Flow	-687	-728	-58	142
Effect of Exchange Rate Changes on Cash and Cash Equivalents	6	20	-14	0
Net Cash Flow	381	323	90	134
Free Cash Flow	1,080	1,072	360	44
Free Cash Flow Growth	0.75%	197.78%	718.18%	-
FCF Margin	18.23%	20.45%	8.11%	1.07%
Free Cash Flow Per Share	4.59	4.52	1.51	0.19
Levered Free Cash Flow	917	689	-1,810	-940
Unlevered Free Cash Flow	1,279	1,164	615.63	-2,791